PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
PUMA BIOTECHNOLOGY, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.21+0.38 (+3.87%)
Close on Oct 19, 2026
- Market cap
- $537.01M
- P/E (TTM)
- 19.6
- Dividend yield
- –
Share price
+$4.74 (+86.65%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
PUMA BIOTECHNOLOGY, INC. saw revenue fall 2.9% to $231.24M over the twelve months to Jun 30, 2026. Operating income fell 33.9% to $30.44M, moving the operating margin from 19.3% to 13.2%. Free cash flow was $41.16M, down 6.9% from a year earlier.
Revenue
$231.24M
-2.9% vs. a year earlier
Operating income
$30.44M
-33.9% vs. a year earlier
Free cash flow
$41.16M
-6.9% vs. a year earlier
EPS, diluted
$0.52
-46.9% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $537.01M
- P/E ratio
- 19.6
- Price to sales
- 2.32
- Price to book
- 3.88
- Dividend yield
- –
- Free cash flow yield
- 7.66%
Fundamentals
- Revenue
- $231.24M
- Net income
- $26.72M
- EPS, diluted
- $0.52
- Free cash flow
- $41.16M
- Book value per share
- $2.63
- Diluted shares
- 53M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$231.24M-2.9% YoY
Gross profit
$173.05M+0.5% YoY
Operating income
$30.44M-33.9% YoY
Net income
$26.72M-44.9% YoY
EPS, diluted
$0.52-46.9% YoY
Free cash flow
$41.16M-6.9% YoY
Reported periodTrailing twelve months